Status:

RECRUITING

Identifying Prognostic Variables for Persistent UL Dysfunctions After Breast Cancer Treatment -Reliability and Validity

Lead Sponsor:

KU Leuven

Collaborating Sponsors:

Universitaire Ziekenhuizen KU Leuven

Vrije Universiteit Brussel

Conditions:

Breast Cancer

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Breast cancer is the most frequently occurring cancer, assuming that it accounts for 29% of all new cancers in women (European Cancer Information System). The number of long-term survivors is increasi...

Eligibility Criteria

Inclusion

  • Inclusion Criteria for breast cancer patients
  • Patients scheduled for surgery (mastectomy or breast conserving surgery; in combination with axillary lymph node dissection or sentinel node biopsy) for unilateral primary breast cancer or patients with oligometastatic breast cancer.
  • Patients who receive adjuvant radiotherapy .
  • Patients with a cognitive and language functioning enabling coherent Dutch communication between the examiner and the participant
  • Patients who can comply with the protocol at baseline assessment and willing to provide written informed consent
  • Inclusion criteria healthy volunteers
  • Healthy women and men(quickDASH\<15) age- and gender-matched with a breast cancer patient from the main study
  • Volunteers who can comply with the protocol at baseline assessment and willing to provide written informed consent
  • Exclusion Criteria breast cancer patients
  • BCS with widespread distance metastases, previous breast surgery, or planned bilateral surgery
  • And/or with a diagnosis of a neurological or rheumatological condition, diabetes,
  • And/or BCS who are not available the entire duration of the study
  • Exclusion Criteria healthy volunteers
  • History of breast cancer
  • Patients with a diagnosis of neurological or rheumatological condition, diabetes

Exclusion

    Key Trial Info

    Start Date :

    April 26 2022

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    February 1 2025

    Estimated Enrollment :

    150 Patients enrolled

    Trial Details

    Trial ID

    NCT05371847

    Start Date

    April 26 2022

    End Date

    February 1 2025

    Last Update

    May 1 2024

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Universitair Ziekenhuis Leuven

    Leuven, Belgium, 3000

    Identifying Prognostic Variables for Persistent UL Dysfunctions After Breast Cancer Treatment -Reliability and Validity | DecenTrialz